Trial · SUSTAIN-6

Semaglutide and cardiovascular outcomes in T2D: SUSTAIN-6

Name: SUSTAIN-6 — Semaglutide and cardiovascular outcomes in T2D: SUSTAIN-6
Published: 2026-01-12

Original CV outcomes trial establishing the CV benefit of semaglutide in T2D. Underpinned the early indication-creep of GLP-1 receptor agonists from glycemic to cardiometabolic therapy.

Outcome

MACE in 6.6% of semaglutide group vs 8.9% placebo (HR 0.74; 95% CI 0.58–0.95; p = 0.02 for superiority). Driven primarily by reductions in non-fatal stroke and non-fatal MI.